Abstract：Objective To explore the diagnosis and treatment of low molecular-weight heparin (LMWH) early onset severe preeclampsia (EOSP) patients curative effect analysis.Methods The clinical data of 72 patients with EOSP who received treatment in Binzhou Medical School Affiliated Hospital from January 2020 to August 2021 were retrospectively analyzed.Thirty six patients receiving conventional treatment were selected as the control group,and thirty six patients receiving low-molecular-weight heparin in addition to conventional treatment were selected as the observation group.Blood pressure,24 h urine protein,amniotic fluid volume,blood coagulation and fibrinolysis function indexes,umbilical artery blood flow indexes and adverse outcomes of maternal and infant were compared between the two groups.Results Each index of two groups of patients before treatment,there was no statistically significant difference(P>0.05).After treatment,the blood pressure,24 hours urinary protein quantitative,plasma fibrinogen (FIB),D-dimer(D-D) and umbilical artery blood flow index of the observation group were lower than before treatment,and the sheep water,activated partial clotting enzyme live time (APTT),prothrombin time (PT) were higher than before treatment,the differences was statistically significant (P<0.05).After treatment,the blood pressure,24 hours urinary protein quantitative,plasma fibrinogen (FIB) and umbilical artery blood flow indicators below of the control group were lower than before treatment,the sheep water was higher than before treatment,the differences were statistically significant (P<0.05).There were no statistically significant difference in D-D,APTT and PT of control group before and after the treatment(P>0.05).After treatment,the blood pressure,24 hours urinary protein quantitative,FIB,D-D and umbilical artery blood flow index of the observation group were lower than those of the control group,and the sheep water,APTT,PT were higher than those of the control group,the differences was statistically significant (P<0.05).After treatment,the incidence of maternal complications and neonatal adverse outcomes in observation group were lower than those in the control group,the differences were statistically significant (P<0.05).Conclusion LMWH treatment of EOSP has a significant therapeutic effect,it can obviously reduce the patient′s blood pressure levels and 24 hours urinary protein quantitative,significantly increase the sheep water,effectively improve blood coagulation fibrinolytic related indicators and related parameters of umbilical artery blood flow,it can gradually restore has damaged fetus-placental blood circulation for the growth and development of the fetus in the womb,it also may be extended appropriately gestational age,reducing the occurrence of aderse outcome mother son,worthy of clinical popularization and application.
刘晶；张亚丽；王宇威；梁葵香. 低分子肝素治疗早发型重度子痫前期患者的疗效分析[J]. 中国当代医药, 2022, 29(14): 22-26.
LIU Jing；ZHANG Yali；WANG Yuwei；LIANG Kuixiang. Effect analysis of low molecular-weight heparin in the treatment of patients with early onset severe preeclampsia. 中国当代医药, 2022, 29(14): 22-26.
Yildirim F，Tuncer B，Ozbakkaloglu A，et al.Thromboelastogram reduces blood use by inspecting coagulation in heart surgery[J].Asian Cardiovasc Thorac Ann，2016，24（5）：441-444.
[5]
Rani DJ，Rani LJ，Poornima P.Evaluation of maternal and perinatal outcomes in elective termination of severe preeclampsia between 28 to 34 weeks in a tertiary care hospital—A retrospective study[J].IAIM，2020，7（1）：1-6.
[6]
Lotufo FA，Parpinelli MA，Osis MJ，et al.Obstetrician's risk perception on the prescription of magnesium sulfate in severe preeclampsia and eclampsia：A qualitative study in Brazil[J].PLoS One，2017，12（3）：e0172602.
Han L，Zhao Y，Jin Z，et al.Correlation of miRNA and VEGF expression with the outcome of early-onset severe preeclampsia in patients receiving expectant treatment[J].Int J Clin Exp Pathol，2018，11（4）：2137-2141.
[14]
蒋维贞.子痫前期抗凝治疗的研究进展[J].实用妇产科杂志，2019，35（12）：910-914.
[15]
Zhou W，Wang H，Wu X，et al.The profile analysis of circular RNAs in human placenta of preeclampsia[J].Exp Biol Med（Maywood），2018，243（14）：1109-1117.
[16]
Ngwenya S，Jones B，Mwembe D，et al.Early onset severe preeclampsia and eclampsia in a low-resource setting，Mpilo Central Hospital，Bulawayo，Zimbabwe[J].BMC Res Notes，2019，12（1）：822.
[17]
Kaartokallio T，Utge S，Klemetti MM，et al.Fetal Microsatellite in the Heme Oxygenase 1 Promoter Is Associated With Severe and Early-Onset Preeclampsia[J].Hypertension，2018，71（1）：95-102.
[18]
Law KP，Han TL，Tong C，et al.Mass spectrometry-based proteomics for pre-eclampsia and preterm birth[J].Int J Mol Sci，2015，16（5）：10 952-10 985.
[19]
van Rein N，Biedermann JS，van der Meer FJM，et al.Major bleeding risks of different low-molecular-weight heparin agents：a cohort study in 12 934 patients treated for acute venous thrombosis[J].J Thromb Haemost，2017，15（7）：1386-1391.
Wang X，Gao H.Prevention of preeclampsia in high-risk patients with low-molecular-weight heparin：a metaanalysis[J].J Matern Fetal Neonatal Med，2020，33（13）：2202-2208.
[22]
Zee AA，van Lieshout K，van der Heide M，et al.Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization[J].Cochrane Database Syst Rev，2017，8（8）：CD006681.
[23]
Ahrens KA，Silver RM，Mumford SL，et al.Complications and Safety of Preconception Low-Dose Aspirin Among Women With Prior Pregnancy Losses[J].Obstet Gynecol，2016 Apr，127（4）：689-698.
京公网安备 11010502046607号